Results 11 to 20 of about 21,239 (239)

Single and combined toxicity of tadalafil (Cilais) and microplastic in Tilapia fish (Oreochromis niloticus)

Scientific Reports
The joint impact of tadalafil (Cilais) as a pharmaceutical residue and microplastics on fish is not well comprehended. The current study examined haematological, biochemical, and antioxidant parameters, along with immunohistochemical and histological ...
Mahmoud S. Sabra, Alaa El-Din H. Sayed, Shaimaa K. A. Idriss, Hamdy A. M. Soliman   +3 more
doaj   +2 more sources

Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Tadalafil in Colorectal Cancer

Frontiers in Pharmacology, 2022
The potential role of tadalafil, a PDE5 inhibitor, in anticancer activity and prolonged survival has been proposed. However, the systematic effects of tadalafil in colorectal cancer were not fully understood.
Pan Zhao, Yao Shen, Mengyang Li, Hanjun Dan, Zhiming Zhao, Jian Zhang   +5 more
doaj   +2 more sources

Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules

BMC Chemistry, 2022
Entadfi™ is a recently FDA approved pharmaceutical combination capsule of finasteride and tadalafil. It was prescribed for the treatment of urinary tract disorders caused by benign prostatic hyperplasia in men.
Ahmed H. Abdelazim, Sherif Ramzy
doaj   +2 more sources

Association of Pericardial Tamponade With Initiation of Sotatercept in a Patient With Eisenmenger Syndrome. [PDF]

Pulm Circ
ABSTRACT Eisenmenger syndrome (ES) represents an advanced stage of pulmonary arterial hypertension (PAH) associated with congenital heart disease. It is characterized by elevated pulmonary vascular resistance, with a right‐to‐left shunt and resting hypoxemia. ES is associated with high morbidity and mortality.
Aldawsari KA, Simpkin CT, Frank BS, Ivy DD.   +3 more
europepmc   +2 more sources

Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial. [PDF]

BJU Int
Objectives To evaluate the efficacy and safety of a fixed‐dose combination (FDC) of dutasteride and tadalafil vs monotherapy in patients with benign prostatic hyperplasia (BPH). Patients and Methods This phase III trial enrolled 667 patients. After screening and washout, eligible patients were stratified by the baseline International Prostate Symptom ...
Lee SW, Lee SH, Kim JH, Noh JH, Lee JH, Ha US, Oh CY, Kang TW, Lee G, Lee S, Han DH, Han JH, Song SH, Park HJ, Chung BH, Min GE, Jeong IG, Moon KH, Kim WT, Lee JY, Kim CS.   +20 more
europepmc   +2 more sources

Application of Box-Behnken Design in the Preparation, Optimization, and In-Vivo Pharmacokinetic Evaluation of Oral Tadalafil-Loaded Niosomal Film

Pharmaceutics, 2023
Benign prostatic hyperplasia (BPH) affects about 90% of men whose ages are over 65. Tadalafil, a selective PDE-5 inhibitor, was approved by FDA for BPH, however, its poor aqueous solubility and bioavailability are considered major drawbacks.
Kawthar K. Abla, A. Mneimneh, Ahmed N Allam, Mohammed M. Mehanna   +3 more
semanticscholar   +1 more source

Portopulmonary hypertension practice patterns after liver transplantation

Liver Transplantation, EarlyView., 2022
Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose, Elizabeth J. Kopras, Shimul A. Shah, Jean M. Elwing   +3 more
wiley   +1 more source

Proniosomal Gel-Loaded Phosphodiesterase Inhibitors (Sildenafil, Vardenafil, and Tadalafil): Prospects for Topical Penile Therapy of Tadalafil for Treatment of Erectile Dysfunction

Gels, 2023
Oral phosphodiesterase inhibitors have emerged as a game changer for the treatment of erectile dysfunction (ED) since attaining FDA approval for its first member, sildenafil, in 1998.
S. A. Mohamed, R. Rofaeil, Hesham Salem, Mahmoud Elrehany, Y. Asiri, Adel Al Fatease, Hamdy Abdelkader   +6 more
semanticscholar   +1 more source

Feasibility of high-dose tadalafil and effects on insulin resistance in well-controlled patients with type 2 diabetes (MAKROTAD): a single-centre, double-blind, randomised, placebo-controlled, cross-over phase 2 trial

EClinicalMedicine, 2023
Summary Background Phosphodiesterase-5 inhibitors exert positive vascular and metabolic effects in type 2 diabetes (T2D), but the effect on insulin resistance in T2D is unclear.
E. Fryk, Vagner Ramon Rodrigues Silva, M. Bauzá-Thorbrügge, M. Schmelz, Lijuan Gan, L. Strindberg, P. Jansson   +6 more
semanticscholar   +1 more source

A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma

Neuro-Oncology Advances, 2023
Background Myeloid-derived suppressor cells (MDSCs) are critical regulators of immunosuppression and radioresistance in glioblastoma (GBM). The primary objective of this pilot phase Ib study was to validate the on-target effect of tadalafil on inhibiting
Subhajit Ghosh, T. Johanns, Milan G. Chheda, E. Liu, O. Butt, C. Abraham, S. Badiyan, Yi Huang, D. DeNardo, A. Kim, D. Hallahan, D. Thotala, Jiayi Huang   +12 more
semanticscholar   +1 more source